Form 4: Exelixis Executive Sells 10,000 Shares Under 10b5-1 Trading Plan

Exelixis EVP, Commercial, Patrick J. Haley, sold 10,000 shares of common stock at $35.27 per share on November 22, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Patrick J. Haley, EVP, Commercial at Exelixis, Inc., sold 10,000 shares of common stock on November 22, 2024, at a price of $35.27 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 19, 2024.
• Following the transaction, Haley directly owns 278,665 shares, which includes 210,622 shares issuable upon vesting of restricted stock units.
• Haley also has indirect ownership of 23,539 shares through his spouse and 10,648 shares through the company's 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for an executive stock sale under a pre-arranged plan, which is neither positive nor negative.

Industry Context

This is a routine filing for insider trading activity and is common for executives who have pre-arranged trading plans. It does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those of other companies.
• The use of a 10b5-1 trading plan is a common method for executives to sell shares without being accused of insider trading, and is used by executives at companies such as Amgen, Gilead, and Regeneron.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect due to the pre-arranged nature of the sale.

Key Dates

Keywords

Exelixis, insider trading, Form 4, stock sale, Rule 10b5-1, executive, equity securities